# A Study of the Quality of Life and Treatment Response to Once Weekly Epoetin Beta (Recormon) Treatment in Anemic Participants With Solid and Lymphoid Malignancies

> **NCT00776425** · PHASE4 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 117 (actual)

## Conditions studied

- Anemia

## Interventions

- **DRUG:** Epoetin beta

## Key facts

- **NCT ID:** NCT00776425
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-01
- **Primary completion:** 2012-11
- **Final completion:** 2012-11
- **Target enrollment:** 117 (ACTUAL)
- **Last updated:** 2017-07-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00776425

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00776425, "A Study of the Quality of Life and Treatment Response to Once Weekly Epoetin Beta (Recormon) Treatment in Anemic Participants With Solid and Lymphoid Malignancies". Retrieved via AI Analytics 2026-09-07 from https://api.ai-analytics.org/clinical/NCT00776425. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*